Plain-English translation of NCT05651932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing KTX-1001, a new medication taken by mouth, for patients with multiple myeloma that has come back or stopped responding to standard treatments. Researchers will first test different doses to find the safest amount, then study how well the medication works when given alone or combined with other existing cancer drugs.
Current treatments for relapsed or refractory multiple myeloma don't work for everyone, and patients need new options. This medication targets a protein involved in cancer cell growth in a way that hasn't been tried before, offering hope for patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth, either alone or combined with one or more standard cancer drugs, depending on which group you're assigned to. The trial has two phases: first, researchers test increasing doses to find the safest amount; then, if you join the expansion phase, you'll receive the medication at that established dose. You'll have regular clinic visits for blood tests and check-ups to monitor how the medication is working and watch for side effects.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States